Harvard Apparatus postpones $19 million IPO

Comment

Shutterstock photo

Harvard Apparatus Regenerative Technology, a Harvard Bioscience carve-out focusing on regenerative medicine, postponed its IPO on Wednesday citing poor market conditions. The Holliston, MA-based company, which was founded in 2009, had expected to raise $18.7 million in its IPO by offering 1.7 million shares at $10 to $12. Summer Street Research Partners and Maxim Group LLC were set to be the joint bookrunners on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: News Headlines , IPOs


More from Renaissance Capital

Subscribe






Renaissance Capital
Contributor:

Renaissance Capital

IPOs
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com